| Developers of biopharma assets need to understand what product attributes will drive demand by prescribers and how their product will compare to existing competitors at launch and vs. future competitors over time. In this Whitepaper, Dr. Bill Brastow, Chief Technology Officer at Rosa Market Modeling, will explain how companies that are commercializing new biopharma assets can use Discrete Choice Modeling to help answer these questions. This article will provide guidance regarding using the Market Model results: To inform internal decisions about new product planning and go/no go decisions To share with investors and partners regarding the commercial potential for your biopharma asset
| 